| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal HST10: Patisiran for treating hereditary transthyretin amyloidosis |
|
Medicine details |
|
| Medicine name | patisiran (Onpattro®) |
| Formulation | 2 mg/ml concentrate for solution for infusion |
| Reference number | 1823 |
| Indication | Treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy |
| Company | Alnylam Pharmaceuticals Inc |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 18/09/2018 |
| NICE guidance | HST10: Patisiran for treating hereditary transthyretin amyloidosis |